Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercept Boosts NASH Commercial Potential Via NICE Rare Disease Move

Executive Summary

With Gilead snapping at its heels in NASH, Intercept will be pleased with its product's positive reimbursement recommendation in the UK for rare disease PBC; physicians will have the opportunity to familiarize themselves with Intercept's offering.

You may also be interested in...



UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?

Novartis is teaming up with Allergan in a bid to get a treatment on the market for the fatty liver disease NASH, which currently has no approved treatments. The decision by Novartis to test its lead FXR agonist with Allergan's cenicriviroc (CVC) is interesting because Allergan's product reported mixed Phase II data.

Intercept Increases Chance Of Success In NASH Without Significant Delay

Ocaliva could now qualify for accelerated approval in NASH by meeting either of two Phase III co-primary endpoints, whereas the trial initially was designed for success on both measures.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel